[go: up one dir, main page]

PL3513804T3 - Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania - Google Patents

Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania

Info

Publication number
PL3513804T3
PL3513804T3 PL18211156T PL18211156T PL3513804T3 PL 3513804 T3 PL3513804 T3 PL 3513804T3 PL 18211156 T PL18211156 T PL 18211156T PL 18211156 T PL18211156 T PL 18211156T PL 3513804 T3 PL3513804 T3 PL 3513804T3
Authority
PL
Poland
Prior art keywords
methods
factor viii
hybrid polypeptides
viii chimeric
chimeric
Prior art date
Application number
PL18211156T
Other languages
English (en)
Inventor
Jennifer A. Dumont
Susan Low
Alan J. Bitonti
Glenn Pierce
Alvin Luk
Haiyan Jiang
Byron Mckinney
Matt Ottmer
Jurg Sommer
Karen Nugent
Lian Li
Robert Peters
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of PL3513804T3 publication Critical patent/PL3513804T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
PL18211156T 2011-07-08 2012-07-06 Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania PL3513804T3 (pl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201161506015P 2011-07-08 2011-07-08
US201161522647P 2011-08-11 2011-08-11
US201161541561P 2011-09-30 2011-09-30
US201161569158P 2011-12-09 2011-12-09
US201261586443P 2012-01-13 2012-01-13
US201261622789P 2012-04-11 2012-04-11
US201261657641P 2012-06-08 2012-06-08
EP12811808.0A EP2729161B1 (en) 2011-07-08 2012-07-06 Factor viii chimeric and hybrid polypeptides, and methods of use thereof
PCT/US2012/045784 WO2013009627A2 (en) 2011-07-08 2012-07-06 Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EP18211156.7A EP3513804B1 (en) 2011-07-08 2012-07-06 Factor viii chimeric and hybrid polypeptides, and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3513804T3 true PL3513804T3 (pl) 2022-07-11

Family

ID=47506823

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18211156T PL3513804T3 (pl) 2011-07-08 2012-07-06 Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
PL12811808T PL2729161T3 (pl) 2011-07-08 2012-07-06 Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12811808T PL2729161T3 (pl) 2011-07-08 2012-07-06 Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania

Country Status (27)

Country Link
US (4) US10010622B2 (pl)
EP (3) EP3513804B1 (pl)
JP (5) JP2014522838A (pl)
KR (2) KR102110736B1 (pl)
CN (2) CN103796670A (pl)
AR (1) AR087091A1 (pl)
AU (3) AU2012282875B2 (pl)
BR (1) BR112014000466A2 (pl)
CA (1) CA2841066C (pl)
CL (1) CL2014000024A1 (pl)
CO (1) CO6940381A2 (pl)
CY (1) CY1122900T1 (pl)
DK (2) DK2729161T3 (pl)
EA (1) EA029045B1 (pl)
ES (2) ES2722209T3 (pl)
HR (2) HRP20220639T1 (pl)
HU (1) HUE043763T2 (pl)
IL (2) IL230333B (pl)
LT (2) LT3513804T (pl)
MX (1) MX350581B (pl)
MY (1) MY180714A (pl)
PL (2) PL3513804T3 (pl)
PT (2) PT2729161T (pl)
RS (2) RS58578B1 (pl)
SI (2) SI2729161T1 (pl)
TW (3) TWI626947B (pl)
WO (1) WO2013009627A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026384T2 (en) * 2003-05-06 2016-06-28 Biogen Hemophilia Inc VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
DK2506868T3 (da) * 2009-12-06 2018-01-29 Bioverativ Therapeutics Inc Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
PL3513804T3 (pl) 2011-07-08 2022-07-11 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
PL2802668T3 (pl) * 2012-01-12 2019-03-29 Bioverativ Therapeutics Inc. Sposoby zmniejszania immunogenności wobec czynnika krzepnięcia viii u pacjentów poddawanych leczeniu czynnikiem krzepnięcia viii
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
ES2959747T3 (es) * 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
PL3666283T3 (pl) * 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
US9984348B2 (en) 2013-11-29 2018-05-29 Fedex Corporate Services, Inc. Context management of a wireless node network
US10453023B2 (en) 2014-05-28 2019-10-22 Fedex Corporate Services, Inc. Methods and node apparatus for adaptive node communication within a wireless node network
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
PH12017501089B1 (en) * 2014-12-10 2022-06-22 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
US11238397B2 (en) 2015-02-09 2022-02-01 Fedex Corporate Services, Inc. Methods, apparatus, and systems for generating a corrective pickup notification for a shipped item using a mobile master node
US10057133B2 (en) 2015-07-08 2018-08-21 Fedex Corporate Services, Inc. Systems, apparatus, and methods of enhanced monitoring for an event candidate associated with cycling power of an ID node within a wireless node network
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
JP6957496B2 (ja) 2016-03-23 2021-11-02 フェデックス コーポレイト サービシズ，インコーポレイティド 無線ノードネットワーク内のノードのブロードキャスト設定を自動調整するための無線ノードベースの方法、その方法を実行する命令を含む非一時的コンピュータ可読媒体、および無線ノードネットワークにおける自動調整ブロードキャストノード装置
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US12257288B2 (en) * 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US10603275B2 (en) 2017-11-07 2020-03-31 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
EP3765065A2 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765053A2 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765064A1 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
SG11202010767SA (en) * 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
EP3962516A4 (en) * 2019-05-03 2023-01-04 Rani Therapeutics, LLC COAGAGING FACTOR PREPARATIONS FOR ADMINISTRATION INTO TISSUES OF THE INTESTINAL TRACT USING AN INGESTIONABLE DRUG DELIVERY DEVICE
EP3736286A1 (en) * 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
WO2020257462A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DE3683980D1 (de) 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5171544A (en) 1988-02-02 1992-12-15 Lang John S Method of mixing fluids in packing media for reactors
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
CA2106079C (en) 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
JP4634036B2 (ja) * 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
HUE026384T2 (en) 2003-05-06 2016-06-28 Biogen Hemophilia Inc VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2633916T3 (es) 2004-11-12 2017-09-26 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
SG123635A1 (en) 2004-12-28 2006-07-26 Nanoscience Innovation Pte Ltd Nanostructured zinc oxide and a method of producing the same
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
JP5448839B2 (ja) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
CL2012001463A1 (es) 2009-12-06 2014-02-07 Bioverativ Therapeutics Inc Uso de un polipeptido factor viii de larga duracion para disminuir la incidencia de episodio de sangrado en sujetos humanos y mantener la homeostasis en un sujeto humano que requiere cirugia.
DK2506868T3 (da) 2009-12-06 2018-01-29 Bioverativ Therapeutics Inc Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
DK2591006T3 (da) * 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
US9611310B2 (en) * 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
PL3513804T3 (pl) 2011-07-08 2022-07-11 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania

Also Published As

Publication number Publication date
DK2729161T3 (en) 2019-04-08
US20250195620A1 (en) 2025-06-19
TWI764092B (zh) 2022-05-11
AU2012282875B2 (en) 2016-04-21
IL271870A (en) 2020-02-27
AU2012282875A1 (en) 2013-05-02
CN107261122A (zh) 2017-10-20
CN103796670A (zh) 2014-05-14
MY180714A (en) 2020-12-07
KR102110736B1 (ko) 2020-05-14
EP2729161B1 (en) 2018-12-19
RS63241B1 (sr) 2022-06-30
KR20140066157A (ko) 2014-05-30
IL230333B (en) 2020-05-31
SI2729161T1 (sl) 2019-05-31
PL2729161T3 (pl) 2019-08-30
US10881742B2 (en) 2021-01-05
HRP20220639T1 (hr) 2022-07-08
JP2023134851A (ja) 2023-09-27
LT2729161T (lt) 2019-04-10
US20140294821A1 (en) 2014-10-02
AR087091A1 (es) 2014-02-12
TW201822788A (zh) 2018-07-01
EA201490039A1 (ru) 2014-06-30
WO2013009627A3 (en) 2013-03-07
LT3513804T (lt) 2022-05-25
US10010622B2 (en) 2018-07-03
CY1122900T1 (el) 2021-05-05
WO2013009627A2 (en) 2013-01-17
MX2014000202A (es) 2014-10-06
JP7273487B2 (ja) 2023-05-15
US20210220476A1 (en) 2021-07-22
JP2022003096A (ja) 2022-01-11
EP3513804A1 (en) 2019-07-24
TWI687226B (zh) 2020-03-11
SI3513804T1 (sl) 2022-07-29
US20180360982A1 (en) 2018-12-20
JP2017088623A (ja) 2017-05-25
EP3513804B1 (en) 2022-03-23
EP4169525A1 (en) 2023-04-26
CL2014000024A1 (es) 2014-11-21
EP2729161A4 (en) 2015-06-24
ES2722209T3 (es) 2019-08-08
EP2729161A2 (en) 2014-05-14
AU2018202936A1 (en) 2018-05-17
JP2019048877A (ja) 2019-03-28
PT3513804T (pt) 2022-06-02
EA029045B1 (ru) 2018-02-28
AU2016204986A1 (en) 2016-08-04
HRP20190535T1 (hr) 2019-05-17
CA2841066C (en) 2023-09-26
CA2841066A1 (en) 2013-01-17
IL271870B (en) 2022-04-01
KR20180020305A (ko) 2018-02-27
HUE043763T2 (hu) 2019-09-30
AU2018202936B2 (en) 2020-07-02
MX350581B (es) 2017-09-11
US12186375B2 (en) 2025-01-07
AU2016204986B2 (en) 2018-05-10
KR101829603B1 (ko) 2018-02-19
JP7636481B2 (ja) 2025-02-26
TW202042838A (zh) 2020-12-01
TWI626947B (zh) 2018-06-21
RS58578B1 (sr) 2019-05-31
BR112014000466A2 (pt) 2017-02-21
ES2913994T3 (es) 2022-06-07
TW201315480A (zh) 2013-04-16
PT2729161T (pt) 2019-04-01
NZ619438A (en) 2016-06-24
JP2014522838A (ja) 2014-09-08
DK3513804T3 (da) 2022-06-20
CO6940381A2 (es) 2014-05-09

Similar Documents

Publication Publication Date Title
IL271870B (en) Factor viii chimeric and hybrid polypeptides and methods of using them
IL260769B (en) Factor viii–fc chimeric and hybrid polypeptides and methods of using them
IL287270A (en) Anti-psgl-1 antibodies and their use
IL260045B (en) Polypeptide structures and their uses
ZA201405094B (en) Chimeric factor viii polypeptides and uses thereof
ZA201400562B (en) Axmi205 variant proteins and methods for their use
IL227732A0 (en) cosmetic use
GB201106130D0 (en) Polypeptide
GB201112985D0 (en) Polypeptide
GB201112849D0 (en) Polypeptide
HUP1100282A2 (en) Protein factor
GB201103169D0 (en) Protein expression